Find a Clinical Trial

Showing 221 - 228 of 228 Trials

  • Nitrous Oxide For Endoscopic Ablation of Refractory Barrett’s Esophagus (NO FEAR-BE)

    Principal Investigator:

    Julian Adin Abrams, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT03554356

    Population:

    Adult

    Phase:

    NA
    dy is to evaluate the safety and effectiveness of using the C2 CryoBalloon Focal Ablation System to treat any remaining Barrett’s Esophagus after receiving Radiofrequency Ablation (RFA). Are you Eligible? (Inclusion Criteria) Are you at least 18 years of age? Do you have a history of esophageal cancer? Are you willing to undergo an experimental treatment for your type of cancer?

  • Post-marketing surveillance of StrataCTX® flexible wound dressing for use as a steroid sparing agent

    Principal Investigator:

    Larisa J. Geskin, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04087629

    Population:

    Adult

    Phase:

    NA
    To assess the use of StrataCTX® as a steroid sparing agent for disorders usually treated with topical steroids. Are you Eligible? (Inclusion Criteria) Age ≥ 18 years Ability to sign informed consent document Patient with a diagnosis of CTCL who have contact dermatitis to topical mechlorethamine gel Patients with a diagnosis of CTCL who have intractable pruritus Patients with a diagnosis of CTCL who rely heavily on topical steroids for symptomatic relief Patients on chemo/immunotherapy with drug induced rash Patients with cutaneous acute graft versus host disease

  • Pilot Study to Assess Feasibility, Acceptability, and Efficacy of a Food Navigation and Food DeliveryIntervention to Reduce Food Insecurity Among Patients with Metastatic Breast Cancer

    Principal Investigator:

    Claire Marie Sathe, MD

    Contact Number:

    212-342-5162

    Population:

    Adult

    Phase:

    NA
    The purpose of this research study to find out how we can best help patients with metastatic (advanced) breast cancer who sometimes worry not having enough food and provide resources to access the food that they need. We want to test an intervention by taking surveys to determine how it affects the patients, their food environment, and their mental health. Are you Eligible? (Inclusion Criteria) Must be 18 years old or older - Must have access to smartphone, tablet, or any type of telephone to complete surveys - Must be able to speak English or Spanish

  • RANDOMIZED NON-INFERIORITY TRIAL COMPARING OVERALL SURVIVAL OF PATIENTS MONITORED WITH SERUM TUMOR MARKER DIRECTED DISEASE MONITORING (STMDDM) VERSUS USUAL CARE IN PATIENTS WITH METASTATIC HORMONE RECEPTOR POSITIVE BREAST CANCER

    Principal Investigator:

    Melissa Accordino, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT03723928

    Population:

    Adult

    Phase:

    NA
    The purpose of this study is to determine if overall survival of patients monitored with serum tumor marker direct disease monitoring (STMDDM) is as good as the overall survival of patients monitored with the usual care. Are you Eligible? (Inclusion Criteria) Do you have hormone positive, HER-2 negative, metastatic breast cancer? Are you 18 years of age or older? Are you willing to be monitored for your disease for the duration of this study?

  • Trial of a Smartphone Application to Improve Medication Adherence among Patients with Cancer

    Principal Investigator:

    Melissa Accordino, MD

    Contact Number:

    212-342-5162

    Population:

    Adult

    Phase:

    NA
    The purpose of this study is to learn about the difficulties patients have with the amount of medication they are required to take and to see if a smart phone application can make that process easier for patients. Patients will be asked to use an application on their smartphone or tablet daily and to come to the clinic once a month for 3 months. Are you Eligible? (Inclusion Criteria) Do you have advanced or metastatic cancer, or a hematologic malignancy? Are you taking, or planning to take at least one oral anti-cancer drug? Do you have access to a mobile phone or tablet that can download...

  • The Acceptability of a Rapid Esophageal Adenocarcinoma Risk Test (REACT)

    Principal Investigator:

    Julian Adin Abrams, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT03366012

    Population:

    Adult

    Phase:

    NA
    This study aims to evaluate the acceptability of a new non-invasive screening device to test for Barrett's esophagus. The investigators will prospectively enroll 100 patients to undergo Cytosponge testing. The time of involvement for an individual will range from 2 weeks to 2 months, depending on the results of the Cytosponge test and time to follow up endoscopy, if indicated. The Cytosponge consists of a 3cm diameter, polyester, medical grade spherical sponge on a string, compressed within a gelatin capsule. The capsule is swallowed while the patient or the research specialist holds onto the...

  • Whole-Food Plant-Based Diet (WFPBD) to Control Weight and Metabo-Inflammation in Overweight/Obese Men with Prostate Cancer Receiving Androgen Deprivation Therapy (ADT): A Multi-Center Randomized Control Trial

    Principal Investigator:

    Mark N. Stein, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05471414

    Population:

    Adult

    Phase:

    NA
    The purpose of this study is to assess the efficacy of a home-delivered whole-food plant- based diet (WFPBD) intervention in promoting weight loss in overweight or obese men with prostate cancer receiving androgen deprivation therapy (ADT), as compared to general nutritional counseling only. Another purpose is to assess how easy or difficult it is for patients to comply with a whole-foods plant-based diet, first when it is delivered to their home and later when they have to prepare it on their own. This trial will test whether an intervention such as a special diet is feasible, i.e., whether...

  • Young, Empowered Strong (YES): A web-based patient-reported symptom monitoring andself-management portal for adolescent and young adult breast cancer survivors

    Principal Investigator:

    Dawn L Hershman, MD, MS, FASCO

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04906200

    Population:

    Pediatrics/Adult

    Phase:

    NA
    The Young, Empowered & Strong (YES) study is opened to women who were diagnosed with breast cancer between the ages of 15 and 39 years. Women will need to be within 3 years of the end of early active treatment (e.g. surgery, chemotherapy not including HER2-directed therapy, radiation), and have no know evidence of breast cancer recurrence. The study team designed a web portal, called YES (Young, Empowered & Strong), with information for breast cancer survivors. A web portal is similar to a website where people go for a specific kind of information. We want to find out if using the YES...

Pages